Bayer and IdeeLab put a 12 month clock on a Brazilian biofungicide programme
Bayer and IdeeLab open a 12 month joint development programme for biofungicides in Brazil. Bayer funds the research, IdeeLab earns royalties.
Bayer and IdeeLab Biotecnologia announced on 4 November 2026 that they will develop biological fungicides together for Brazilian farmers. AgFunderNews reports a 12 month research and development partnership covering the full product development cycle, after which the two companies intend to show results and move a candidate forward through registration, field trials and go to market work.
IdeeLab is a biotechnology company and contract development and manufacturing organisation based in Piracicaba, in the Brazilian state of São Paulo, led by founder and chief executive Ronaldo Dalio. It brings an exclusive microbial collection selected for tropical pests and diseases, together with the bioprocess engineering used to assess efficacy and shelf life. The company has more than 30 products on the market and more than 60 partners, among them Syngenta and ICL, and three candidates already in field trials in Brazil.
Neither side disclosed the money. The Brazilian outlet Piranot reports that Bayer makes an initial investment to fund the research and that royalties flow to IdeeLab if the technology advances commercially, with a product expected to reach the market in about four years. In the same week Bayer said it would launch 17 new biological products in Latin America by 2030. Antônio Soares, who heads biologicals for Latin America at Bayer, told Piranot that the biological is meant to sit alongside chemical fungicides rather than replace them.
AgFunderNews reports that the companies have not named the pathogens or crops they will target first. Piranot reports that the programme starts with soybean foliar disease and names target spot. The commercial pressure behind the work is fungicide resistance, which is pushing up application frequency and production costs. “Growers need more and better options to manage these problems,” said Benoit Hartmann, insights, innovation and partnerships lead at Bayer's Crop Science division. Dalio put it more plainly: “It's about joining forces to develop a product as fast as we can.”
What this is worth to an AgTech founder is the structure, not the headline. A 12 month development window with a defined deliverable is a cheap option for the corporate and an expensive one for the startup, so the terms that decide the outcome are who owns the registration dossier, what happens to the strains if the gate is missed, and whether the royalty attaches to the finished product or only to the formulation built on your strain. Note also what IdeeLab brought to the table: more than 30 products already on the market, three candidates already in Brazilian field trials and the capacity to manufacture them. That is the currency corporates pay for in biologicals, and it explains why Brazil keeps absorbing partnership money while European registration timelines run long. Founders in Europe sitting on a promising strain should ask whether their first commercial trials belong in a tropical market, several years ahead of approval at home.
Bayer and IdeeLab put a 12 month clock on a Brazilian biofungicide programme
The German group and a biotech company from Piracicaba will run a joint development cycle for biological fungicides, with Bayer funding the research and royalties flowing back to IdeeLab.
Bayer and IdeeLab Biotecnologia announced on 4 November 2026 that they will develop biological fungicides together for Brazilian farmers. AgFunderNews reports a 12 month research and development partnership covering the full product development cycle, after which the two companies intend to show results and move a candidate forward through registration, field trials and go to market work.
IdeeLab is a biotechnology company and contract development and manufacturing organisation based in Piracicaba, in the Brazilian state of São Paulo, led by founder and chief executive Ronaldo Dalio. It brings an exclusive microbial collection selected for tropical pests and diseases, together with the bioprocess engineering used to assess efficacy and shelf life. The company has more than 30 products on the market and more than 60 partners, among them Syngenta and ICL, and three candidates already in field trials in Brazil.
Neither side disclosed the money. The Brazilian outlet Piranot reports that Bayer makes an initial investment to fund the research and that royalties flow to IdeeLab if the technology advances commercially, with a product expected to reach the market in about four years. In the same week Bayer said it would launch 17 new biological products in Latin America by 2030. Antônio Soares, who heads biologicals for Latin America at Bayer, told Piranot that the biological is meant to sit alongside chemical fungicides rather than replace them.
AgFunderNews reports that the companies have not named the pathogens or crops they will target first. Piranot reports that the programme starts with soybean foliar disease and names target spot. The commercial pressure behind the work is fungicide resistance, which is pushing up application frequency and production costs. “Growers need more and better options to manage these problems,” said Benoit Hartmann, insights, innovation and partnerships lead at Bayer's Crop Science division. Dalio put it more plainly: “It's about joining forces to develop a product as fast as we can.”
What this is worth to an AgTech founder is the structure, not the headline. A 12 month development window with a defined deliverable is a cheap option for the corporate and an expensive one for the startup, so the terms that decide the outcome are who owns the registration dossier, what happens to the strains if the gate is missed, and whether the royalty attaches to the finished product or only to the formulation built on your strain. Note also what IdeeLab brought to the table: more than 30 products already on the market, three candidates already in Brazilian field trials and the capacity to manufacture them. That is the currency corporates pay for in biologicals, and it explains why Brazil keeps absorbing partnership money while European registration timelines run long. Founders in Europe sitting on a promising strain should ask whether their first commercial trials belong in a tropical market, several years ahead of approval at home.